| Metric | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Cash and cash equivalents | $3.2M-57.3% | $7.6M-43.4% | $13.4M |
| Accounts receivable | $556K | $0-100.0% | $96K |
| Prepaid expenses | $421K-4.8% | $442K-45.1% | $805K |
| Other current assets | $16K+45.5% | $11K-98.0% | $537K |
| Total current assets | $4.2M-47.3% | $8.0M-45.9% | $14.8M |
| Other investment | $5.3M+0.0% | $5.3M | $0 |
| Total assets | $9.6M-28.4% | $13.4M-26.0% | $18.1M |
| Accounts payable | $390K-67.4% | $1.2M-59.7% | $3.0M |
| Accrued research and development costs | $52K-42.2% | $90K-96.0% | $2.3M |
| Accrued expenses and other current liabilities | $283K-64.5% | $798K-66.5% | $2.4M |
| Total current liabilities | $725K-65.2% | $2.1M-72.6% | $7.6M |
| Commitments and contingencies (Note 8) | $0 | $0 | $0 |
| Preferred stock, no par value, 100,000,000 shares authorized and 351,037 shares of Series A convertible preferred stock issued and outstanding at December 31, 2024 and 2023 | $0 | $0 | $0 |
| Common stock, no par value, 400,000,000 shares authorized at December 31, 2024 and 2023; 2,710,096 and 2,645,096 shares issued at December 31, 2024 and 2023, respectively; 2,545,922 and 2,474,159 shares outstanding at December 31, 2024 and 2023, respectively | 0 | 0 | 0 |
| Paid-in capital | $276.3M+0.2% | $275.7M+2.3% | $269.6M |
| Accumulated deficit | -$267.5M-1.2% | -$264.4M-2.0% | -$259.2M |
| Accumulated other comprehensive loss | $0+100.0% | -$12K+40.0% | -$20K |
| Total stockholders' equity | $8.8M-21.6% | $11.3M+8.0% | $10.5M |
| Total liabilities and stockholders' equity | $9.6M-28.4% | $13.4M-26.0% | $18.1M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.